

Program of Research to Transform Indigenous Primary Healthcare Delivery: Community-driven Innovations and Strategic Scale-up Toolkits



Stewart B. Harris, MD, Mariam Nagshbandi Hayward, MSc, Jann Paquette-Warren, MSc, Michael Green, MD, Susan Webster-Bogaert, MA, Selam Meguanint, M.Tech, Rosie Caruso, BA, Meghan Fournie, BHSc. *On behalf of the FORGE AHEAD Program Team



INTRODUCTION

- Indigenous peoples experience 2-5 times higher prevalence rates of T2DM than the general population and significantly worse health outcomes 1,2,3
- A wide array of factors underlie this disparity in prevalence rates and health outcomes, including: social determinants of health, lifestyle, genetic susceptibility, historic-political and psycho-social factors, fragmented healthcare, poor chronic disease management, healthcare staff turnover, and limited, or non-existent, surveillance 4,5

OBJECTIVE

- The TransFORmation of IndiGEnous PrimAry HEAlthcare Delivery (FORGE AHEAD) Program is a national intervention aimed at improving the care of Indigenous peoples diagnosed with T2DM
- FORGE AHEAD aims to develop and evaluate communitydriven, culturally relevant, primary healthcare models that enhance chronic disease prevention and management
- Such quality improvement/healthcare reform interventions have been conducted in the general population, but FORGE AHEAD is the **first of its kind** targeting healthcare delivery in Indigenous community settings

DESIGN

 Founded in community-based participatory action research principles and honoring OCAP® principles, a mixed-method (chart audits, surveys and interviews), multi-repeated measures (baseline, 6-12-18 months post) observational design will be used

MEASURES

- **Primary**: mean A1C of patients with diabetes
- Secondary: clinical process and outcome measures, change in stage of readiness, participant description of facilitators and barriers related to developing innovations
- To detect an absolute 0.5% mean HbA1c difference, a total of 586 patients are required


PARTICIPANTS

- 12 Canadian Indigenous communities
- 3-5 team members per community for a **Clinical Team and a Community Team**
- Adults (18 years and older) with T2DM and most recent HbA1C above target (≥ 8.0%)



INTERVENTION

- Series of inter-related quality improvement activities designed to foster community-driven innovations with **T2DM** as the action disease
- Three waves of implementation will occur to maximize participation – October 2014 to March 2016; April 2015 to September 2016; October 2015 to March 2017



- Dyck, Nagshbandi Hayward, Harris, on behalf of the CIRCLE Study Group, 2012
- 3. Dyck, Osgood, Lin, Gao, Stang, 2010
- 4. Gracev and King, 2009.
- 5. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013

PROGRESS UPDATE

- National Community Profile Survey distributed to 485 communities across Canada
- 1st wave (six Indigenous communities) have started their program activities

ANTICPATED RESULTS

- We anticipate that FORGE AHEAD will result in:
 - An **improvement** in the stage of **readiness** for our partnering communities
 - Development of an up-to-date diabetes registry and **surveillance** system to track T2DM clinical outcomes
 - **Increased capacity** in the community to use quality improvement tools to develop, implement, and monitor community and clinic innovations that will result in **improvements** in **blood sugar control** and other related clinical processes and outcomes

CONCLUSIONS

• Indigenous community and clinic quality improvement initiatives can result in **community-driven innovations** that enhance chronic disease prevention and management for **improved health** of **Indigenous peoples** with diabetes in Canada

*Our multi-disciplinary and cross-jurisdictional CBPHC Team consists of Indigenous community representatives, Indigenous and non-Indigenous healthcare professionals, clinician scientists, academic researchers and organizational and government partners. A complete list of the FORGE AHEAD Program Team is included in the appended handout.

This research program is supported by the Canadian Institutes of Health Research, the Lawson Foundation and AstraZeneca.





